{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:50:55Z","timestamp":1786704655723,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T00:00:00Z","timestamp":1575590400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T00:00:00Z","timestamp":1575590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s13760-019-01252-x","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T10:02:37Z","timestamp":1575626557000},"page":"133-140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Late-onset generalized myasthenia gravis: clinical features, treatment, and outcome"],"prefix":"10.1007","volume":"120","author":[{"given":"Senay","family":"Yildiz Celik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hacer","family":"Durmus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vuslat","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guher","family":"Saruhan Direskeneli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesim","family":"Gulsen Parman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piraye","family":"Serdaroglu Oflazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feza","family":"Deymeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,6]]},"reference":[{"issue":"5","key":"1252_CR1","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1212\/WNL.40.5.786","volume":"40","author":"DH Donaldson","year":"1990","unstructured":"Donaldson DH et al (1990) The relationship of age to outcome in myasthenia gravis. Neurology 40(5):786\u2013790","journal-title":"Neurology"},{"key":"1252_CR2","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/j.1749-6632.1998.tb11017.x","volume":"841","author":"G Slesak","year":"1998","unstructured":"Slesak G et al (1998) Late-onset myasthenia gravis. Follow-up of 113 patients diagnosed after age 60. Ann N Y Acad Sci 841:777\u2013780","journal-title":"Ann N Y Acad Sci"},{"issue":"11","key":"1252_CR3","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1111\/j.1532-5415.2000.tb02635.x","volume":"48","author":"A Evoli","year":"2000","unstructured":"Evoli A et al (2000) Clinical characteristics and prognosis of myasthenia gravis in older people. J Am Geriatr Soc 48(11):1442\u20131448","journal-title":"J Am Geriatr Soc"},{"key":"1252_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000061632","volume-title":"Neuromuscular diseases: from basic mechanisms to clinical management","author":"F Deymeer","year":"2000","unstructured":"Deymeer F et al (2000) Juvenile and late-onset myasthenia gravis. In: Deymeer F (ed) Neuromuscular diseases: from basic mechanisms to clinical management. Karger, Basel, pp 113\u2013127"},{"key":"1252_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1196\/annals.1254.055","volume":"998","author":"JA Aarli","year":"2003","unstructured":"Aarli JA et al (2003) Myasthenia gravis in individuals over 40. Ann N Y Acad Sci 998:424\u2013431","journal-title":"Ann N Y Acad Sci"},{"issue":"1\u20132","key":"1252_CR6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jneuroim.2010.10.023","volume":"230","author":"S Suzuki","year":"2011","unstructured":"Suzuki S et al (2011) Clinical and immunological differences between early and late-onset myasthenia gravis in Japan. J Neuroimmunol 230(1\u20132):148\u2013152","journal-title":"J Neuroimmunol"},{"issue":"10","key":"1252_CR7","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1007\/s00415-012-6478-6","volume":"259","author":"SA Zivkovic","year":"2012","unstructured":"Zivkovic SA et al (2012) Characteristics of late-onset myasthenia gravis. J Neurol 259(10):2167\u20132171","journal-title":"J Neurol"},{"key":"1252_CR8","first-page":"740583","volume":"2011","author":"S Suzuki","year":"2011","unstructured":"Suzuki S et al (2011) Three types of striational antibodies in myasthenia gravis. Autoimmune Dis 2011:740583","journal-title":"Autoimmune Dis"},{"issue":"3","key":"1252_CR9","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/brain\/103.3.579","volume":"103","author":"DA Compston","year":"1980","unstructured":"Compston DA et al (1980) Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 103(3):579\u2013601","journal-title":"Brain"},{"key":"1252_CR10","doi-asserted-by":"crossref","unstructured":"Seldin MF et al (2015) Genome-wide association study of late-onset myasthenia gravis: confirmation of TNFRSF11A, and identification of ZBTB10 and three distinct HLA associations. Mol Med","DOI":"10.2119\/molmed.2015.00232"},{"key":"1252_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.clim.2016.05.003","volume":"166\u2013167","author":"G Saruhan-Direskeneli","year":"2016","unstructured":"Saruhan-Direskeneli G et al (2016) Genetic heterogeneity within the HLA region in three distinct clinical subgroups of myasthenia gravis. Clin Immunol 166\u2013167:81\u201388","journal-title":"Clin Immunol"},{"issue":"7","key":"1252_CR12","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.nmd.2017.04.002","volume":"27","author":"E Santos","year":"2017","unstructured":"Santos E et al (2017) HLA and age of onset in myasthenia gravis. Neuromuscul Disord 27(7):650\u2013654","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"1252_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/ane.12271","volume":"130","author":"P Szczudlik","year":"2014","unstructured":"Szczudlik P et al (2014) Antititin antibody in early- and late-onset myasthenia gravis. Acta Neurol Scand 130(4):229\u2013233","journal-title":"Acta Neurol Scand"},{"key":"1252_CR14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000212371","volume":"26","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN (2009) Myasthenia gravis with anti-acetylcholine receptor antibodies. Front Neurol Neurosci 26:94\u2013108","journal-title":"Front Neurol Neurosci"},{"issue":"1","key":"1252_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/archneur.56.1.25","volume":"56","author":"JA Aarli","year":"1999","unstructured":"Aarli JA (1999) Late-onset myasthenia gravis: a changing scene. Arch Neurol 56(1):25\u201327","journal-title":"Arch Neurol"},{"issue":"10","key":"1252_CR16","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE et al (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14(10):1023\u20131036","journal-title":"Lancet Neurol"},{"key":"1252_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1749-6632.2012.06780.x","volume":"1275","author":"M Benatar","year":"2012","unstructured":"Benatar M et al (2012) Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial. Ann N Y Acad Sci 1275:17\u201322","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"1252_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55(1):16\u201323","journal-title":"Neurology"},{"issue":"6","key":"1252_CR19","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1002\/mus.21185","volume":"38","author":"TM Burns","year":"2008","unstructured":"Burns TM et al (2008) Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve 38(6):1553\u20131562","journal-title":"Muscle Nerve"},{"issue":"1\u20132","key":"1252_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jns.2011.03.004","volume":"305","author":"H Murai","year":"2011","unstructured":"Murai H et al (2011) Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. J Neurol Sci 305(1\u20132):97\u2013102","journal-title":"J Neurol Sci"},{"issue":"6","key":"1252_CR21","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J et al (1998) A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 50(6):1778\u20131783","journal-title":"Neurology"},{"issue":"5","key":"1252_CR22","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s004150050604","volume":"247","author":"F Romi","year":"2000","unstructured":"Romi F et al (2000) Muscle autoantibodies in subgroups of myasthenia gravis patients. J Neurol 247(5):369\u2013375","journal-title":"J Neurol"},{"issue":"2","key":"1252_CR23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D et al (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37(2):141\u2013149","journal-title":"Muscle Nerve"},{"key":"1252_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4137\/JCM.S29601","volume":"6","author":"N Nishikawa","year":"2015","unstructured":"Nishikawa N et al (2015) Treatment of myasthenia gravis in patients with elderly onset at advanced age. Jpn Clin Med 6:9\u201313","journal-title":"Jpn Clin Med"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-019-01252-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13760-019-01252-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-019-01252-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T00:52:11Z","timestamp":1607129531000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13760-019-01252-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,6]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1252"],"URL":"https:\/\/doi.org\/10.1007\/s13760-019-01252-x","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,6]]},"assertion":[{"value":"27 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of the Medical Ethical Committee at the Istanbul Medical Faculty, Istanbul University (no.: 2013\/95) and the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}